ERBB2 and breast carcinoma: In addition, decreased OS was noted in the high A20-expressing HER2-positive subtype (Fig 2E; HR 4.440, 95% CI 1.902–10.365, P < 0.001) and TNBC subtypes subtype (Fig 2F; HR 2.842, 95% CI 1.060–7.617, P = 0.030) of breast cancer, but it was not observed in the luminal/HER2-negative subtype (Fig 2D; HR 1.970, 95% CI 0.795–4.884, P = 0.135).